Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes

Summary

This is a Phase 2, therapeutic exploratory study designed to evaluate the safety and efficacy of PG-102 compared with placebo. Part A includes Cohort A, comprising participants with type 2 diabetes mellitus (T2DM). Part B includes two cohorts: Cohort B1, enrolling participants with obesity, and Cohort B2, enrolling participants with both obesity and T2DM.

Timeline

Start

2024-12-05

Primary completion

2025-10-30

Completion

2025-10-30

Drugs

Indications